Psychedelic drugs enlighten a 2.5 trillion dollar problem
“Investing in psychedelic medicine thus seems a no-brainer…it may be too much to expect ‘shroom bonds to catch on in the next 12 months. But after psychedelic medicine’s fraught trip to scientific rehabilitation, an alternative reality is now here…the cost of mental illness globally was as much as $2.5 trillion in 2010 and could more than double by 2030, reckons the World Economic Forum. Using those numbers, medical journal the Lancet has argued that investments in mental-health treatment have high returns. If $10 billion were invested every year from now until 2030, the net present value of enhanced economic productivity might be $400 billion.”
Despite its status as a controlled substance, psilocybin has started going into traditional late-stage pharmaceutical development. International trials are slated for the Netherlands, Norway and the United Kingdom over the next two years – and could be extended to other countries. Commercialising psilocybin could be knotty. Innovative financial solutions will probably be required to fund the costs of specialist training for supervisors and the production of pharmaceutical-grade quality. It may be too much to expect ‘shroom bonds to catch on in the next 12 months. But after psychedelic medicine’s fraught trip to scientific rehabilitation, an alternative reality is now here.